Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minoxidil + finasteride is a fixed-dose combination of two pharmaceutical agents used primarily for the treatment of androgenetic alopecia (male pattern hair loss). Minoxidil acts as a vasodilator that increases blood flow to hair follicles and stimulates their growth. Finasteride is a 5-alpha-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), a hormone implicated in hair follicle miniaturization and progressive hair loss. The combination can be administered topically or as separate oral/topical regimens. Clinical studies indicate that using both drugs together provides superior efficacy compared to monotherapy with either agent alone while maintaining similar safety profiles[1][2][3][4][5]. This approach addresses different mechanisms underlying male pattern baldness—minoxidil directly stimulates follicles while finasteride targets hormonal causes—resulting in improved outcomes for patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on minoxidil + finasteride.